Lung Adeno-2™
TTF-1 has been the premier marker for lung adenocarcinoma. A new and promising marker, Napsin A, is expressed in type II pneumocytes and in adenocarcinomas of the lung. Studies have shown Napsin A to be more sensitive and specific than TTF-1 in lung adenocarcinomas and virtually negative in all squamous carcinomas. In other studies comparing TTF-1 and SP-A, Napsin A stained more tumor cells and a higher percentage of lung adenocarcinomas than either of these antibodies. Other studies have shown that when TTF-1 and Napsin A are used in combination, a higher sensitivity and specificity is achieved. A critical assessment is essential for correct diagnosis as patients with squamous carcinoma (SqCC) cannot receive Avastin due to a 30% mortality rate as a result of fatal hemoptysis (hemorrhaging). Therefore, when used in a panel with p63 and CK5, this unique antibody cocktail of TTF-1 and Napsin A should prove useful for immunohistochemical analysis of poorly differentiated lung adenocarcinomas versus squamous cell carcinomas in formalin-fixed paraffinembedded tissues.
| Ordering Information |
Catalog Number |
Volume |
| Concentrate |
N/A |
N/A |
| Predilute |
PPM 394DS |
AA |
| intelliPATH™ |
N/A |
N/A |
| VP Echelon |
N/A |
N/A |
| A / AK = 0.1 ml |
B / BK = 0.5 ml |
C / CK = 1.0 ml |
G5 = 5.0 ml |
AA = 6.0 ml |
H / G25 = 25 ml |
L = 100 ml |
